Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children

NCT01635647 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT01635647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01635647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children
Lead sponsor
University of Oxford
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2012
Completion date
September 30, 2014
Enrollment
730 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria